December 11, 2017 / 10:49 AM / 2 years ago

BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash

Dec 11 (Reuters) - Affimed Nv:

* Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash

* Affimed NV - completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated

* Affimed - 3-month ORR compares favorably to historical ORR of pembrolizumab alone in Phase 1B combination study of aFM13

* Affimed NV - one dose-limiting toxicity observed in Cohort 3, which was repeated GRADE 2 infusion-related reaction

* Affimed NV - In Cohort 3, repeated Grade 2 infusion-related reaction lead to discontinuation of AFM13 treatment Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below